Evaluation of the GenoType (R) MTBDRsl assay for susceptibility testing of second-line anti-tuberculosis drugs

Show simple item record

dc.contributor.author Said, H.M. (Halima Mohammed)
dc.contributor.author Kock, Marleen M.
dc.contributor.author Ismail, Nazir Ahmed
dc.contributor.author Baba, Kamaldeen A.
dc.contributor.author Omar, S.V. (Shaheed Vally)
dc.contributor.author Osman, Ayman G.
dc.contributor.author Hoosen, Anwar Ahmed
dc.contributor.author Ehlers, M.M. (Marthie Magdaleen)
dc.date.accessioned 2012-03-19T06:55:21Z
dc.date.available 2012-03-19T06:55:21Z
dc.date.issued 2012-01
dc.description.abstract BACKGROUND: The GenoType® MTBDRsl assay (Hains, Lifesciences, Germany) is a new rapid assay for detection of resistance to second-line anti-tuberculosis drugs. METHOD: The MTBDRsl assay was evaluated on 342 MDR-TB isolates for ofloxacin (OFX), kanamycin (KAN), capreomycin (CAP) and ethambutol (EMB) resistance and results were compared to the agar proportion method. Discrepant results were tested by DNA sequencing. RESULT: The sensitivity and specificity of MTBDRsl assay was 70.3% and 97.7% for OFX, 25.0% and 98.7% for KAN, 21.2% and 98.7% for CAP and 56.3% and 56.0% for EMB, respectively. DNA sequencing identified mutation that were not detected by MTBDRsl assay including: 8/11 phenotypically OFX-resistant isolates had mutation in gyrA (2/8 had additional mutation in the gyrB gene), 1/11 had mutation only in the gyrB gene; 6/21 phenotypically KAN-resistant isolate had mutation in rrs gene; 7/26 and 20/26 phenotypically CAP-resistant isolates had mutation in the rrs and tlyA genes, respectively. CONCLUSION: The MTBDRsl assay showed a lower sensitivity as compared to previous studies. The assay performed favourably for OFX; however the assay was less sensitive for detection of KAN/CAP resistance and demonstrated low sensitivity and specificity for EMB resistance. It is recommended that the MTBDRsl assay should include additional genes to achieve a better sensitivity for all the drugs tested. en_US
dc.description.sponsorship A grant from the NHLS and Hains, Lifesciences. en_US
dc.description.uri http://www.theunion.org/about-the-journal/about-the-journal.html en_US
dc.identifier.citation Said, HM, Kock, MM, Ismail, NA, Baba, K, Omar, SV, Osman, AG, Hoosen, AA & Ehlers, MM 2012, 'Evaluation of the GenoType (R) MTBDRsl assay for susceptibility testing of second-line anti-tuberculosis drugs', International Journal of Tuberculosis and Lung Disease, vol. 16, no. 1, pp. 104-109. en_US
dc.identifier.issn 1027-3719 (print)
dc.identifier.issn 1815-7920 (online)
dc.identifier.uri http://hdl.handle.net/2263/18471
dc.language.iso en en_US
dc.publisher International Union Against Tuberculosis and Lung Disease en_US
dc.rights International Union Against Tuberculosis and Lung Disease. This article is embargoed by the publisher until July 2012. en_US
dc.subject MDR-TB en_US
dc.subject XDR-TB en_US
dc.subject Genotype® MTBDRsl en_US
dc.subject Drug resistance en_US
dc.subject.lcsh Tuberculosis -- Treatment en
dc.subject.lcsh Multidrug resistance -- Research en
dc.title Evaluation of the GenoType (R) MTBDRsl assay for susceptibility testing of second-line anti-tuberculosis drugs en_US
dc.type Postprint Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record